Lundbeckfond Ventures contributed to a round that will fund clinical trials for Reneo Pharmaceuticals' mitochondrial disease therapies.
Reneo Pharmaceuticals, a US-based developer of treatments for mitochondrial diseases, closed a $50m series A round featuring Lundbeckfonden Ventures, the strategic investment arm of pharmaceutical company Lundbeck, yesterday.
New Enterprise Associates (NEA) led the round, which included fellow venture capital firm RiverVest Venture Partners and life sciences investment firm Pappas Capital.
Reneo is working on therapies for genetic mitochondrial diseases, in which genes in cells’ mitochondria mutate and are unable to generate energy from food fats, leading to cramps, pain…
